CD274 and prostate carcinoma: The upregulation of antitumoral immune response and PD1/PD-L1 expression by chemotherapy prompted us to explore the possibility of combining docetaxel with anti-PD1 blockade in treating prostate cancer, especially in treating CRPC patients.